Compare Gilead Sciences, Inc. (GILD) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs NextEra Energy, Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.56 (market cap $163.51B), while NextEra Energy, Inc. trades at $89.12 (market cap $185.83B). The key difference: Gilead Sciences, Inc. and NextEra Energy, Inc. are close in size by market cap, and NextEra Energy, Inc. pays the higher dividend (2.8%). Which is the better fit depends on your goals.
| GILD | NEE | |
|---|---|---|
Market Cap | $163.51B | $185.83B |
Sector | Health | Utilities |
52-Week High | $155.80 | $97.88 |
52-Week Low | $108.22 | $69.77 |
Enterprise Value | $178.05B | $288.23B |
Dividend Yield | 2.49% | 2.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
NextEra Energy (NEE) trades at $89.12, down 0.47% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $103.00. The company reported strong revenue of $27.41 billion in 2025 and a net income margin of 29.37%, though earnings have shown mixed quarterly results. Recent news highlights a proposed combination with Dominion Energy, which could reshape its geographic footprint and data center exposure.
The outlook for NEE remains positive due to robust profitability, a high analyst buy rating (66.66%), and strategic growth initiatives. Key risks include regulatory hurdles from the Dominion deal and rising debt levels, with the debt-to-asset ratio climbing to 47.6% in 2025. Investors should weigh the potential for earnings-driven upside against execution and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
